ReviewCurrent opinion in pharmacology2012
New horizons for host defense peptides and lantibiotics.
Review in Current opinion in pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 46 citations in OpenAlex.
- Nanomedicine for drug resistant pathogens and COVID-19 using mushroom nanocomposite inspired with bacteriocin - A review.Inorganic chemistry communications · 2023Review
- Lactic Acid Bacteria (LAB): Autochthonous and Probiotic Microbes for Meat Preservation and Fortification.Foods (Basel, Switzerland) · 2022Review
- Semisynthetic Macrocyclic Lipo-lanthipeptides Display Antimicrobial Activity Against Bacterial Pathogens.ACS synthetic biology · 2021Article
- Nisin- and Ripcin-Derived Hybrid Lanthipeptides Display Selective Antimicrobial Activity againstACS synthetic biology · 2021Article
- Biotechnological Insights on the Expression and Production of Antimicrobial Peptides in Plants.Molecules (Basel, Switzerland) · 2021Review
- Bacteriocins in the Era of Antibiotic Resistance: Rising to the Challenge.Pharmaceutics · 2021Review
- Ultra-Short Antimicrobial Peptoids Show Propensity for Membrane Activity Against Multi-Drug ResistantFrontiers in microbiology · 2020Article
- Insights in the Antimicrobial Potential of the Natural Nisin Variant Nisin H.Frontiers in microbiology · 2020Article
- Genome mining, isolation, chemical synthesis and biological evaluation of a novel lanthipeptide, tikitericin, from the extremophilic microorganismChemical science · 2018Article
- Incorporation of Nonproteinogenic Amino Acids in Class I and II Lantibiotics.ACS chemical biology · 2018Article
- Fighting biofilms with lantibiotics and other groups of bacteriocins.NPJ biofilms and microbiomes · 2018Review
- Exploring the links between peptoid antibacterial activity and toxicity.MedChemComm · 2017Article
- Characterization of the stereochemical configuration of lanthionines formed by the lanthipeptide synthetase GeoM.Biopolymers · 2016Article
- Lanthipeptides: chemical synthesis versus in vivo biosynthesis as tools for pharmaceutical production.Microbial cell factories · 2016Review
- Candidacidal Activity of Selected Ceragenins and Human Cathelicidin LL-37 in Experimental Settings Mimicking Infection Sites.PloS one · 2016Article
- In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.Antimicrobial agents and chemotherapy · 2015Article
- Bioengineering Lantibiotics for Therapeutic Success.Frontiers in microbiology · 2015Review
- Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus.Frontiers in immunology · 2014Review
- Contributions of the σ(W) , σ(M) and σ(X) regulons to the lantibiotic resistome of Bacillus subtilis.Molecular microbiology · 2013Article
- Chemical synthesis of the lantibiotic lacticin 481 reveals the importance of lanthionine stereochemistry.Journal of the American Chemical Society · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Antimicrobial peptides from either microbial sources, or based on host defense peptides (HDPs) from higher organisms, show promising activity against human pathogens. Lantibiotics have been extensively engineered by either molecular biology approaches or chemistry and both natural and modified entities have been shown to have good efficacy in animal models of infection. Amongst HDPs either truncated peptides or non-peptide mimetic molecules show substantial promise both for their direct antibiotic action and also modulation of host functions. Members of both classes have reached clinical development for therapy of systemic infections and Clostridium difficile infection of the gastrointestinal tract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.